1378928-84-7

Basic information

• Product Name: (4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)phenyl)methanol
• Synonyms: (4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)phenyl)methanol
• CAS NO: 1378928-84-7
• Molecular Weight: 338.401
• Mol File: 1378928-84-7.mol

Chemical Properties

• CAS DataBase Reference: (4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)phenyl)methanol(1378928-84-7)
• EPA Substance Registry System: (4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)phenyl)methanol(1378928-84-7)

Safety Data

• Hazardous Substances Data: 1378928-84-7(Hazardous Substances Data)

Upstream product

• 87450-10-0 3,6,9,12-tetraoxapentadec-14-yn-1-ol 
• 112-60-7 Tetraethylene glycol 
• 1378928-83-6 4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzaldehyde 
• 1233816-83-5 methanesulfonic acid 2-{2-[2-(2-prop-2-ynyloxyethoxy)ethoxy]ethoxy}ethyl ester 

Downstream Products

• 1378928-89-2 (R)-2-(N-(4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzyl)-4-methoxyphenylmethoxyphenylsulfonamido)-3-methylbutanoic acid 
• 1378928-90-5 (2R)-2-(N-(4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzyl)-4-methoxyphenylsulfonamido)-3-methyl-N-((tetrahydro-2H-pyran-2-yl)oxy)butanamide 
• 1378928-91-6 (R)-2-(N-(4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1378929-00-0 (R)-2-(N-(4-((1-(1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yl)oxy)benzyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1378929-01-1 (R)-2-(N-(4-((1-(1-(2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yl)oxy)benzyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1378929-02-2 (R)-2-(N-(4-((1-(1-((2R,3R,4S,5S,6R)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yl)oxy)benzyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1378928-86-9 1-(4-(bromomethyl)phenoxy)-3,6,9,12-tetraoxapentadec-14-yne 
• 1378928-88-1 (R)-tert-butyl 2-(N-(4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzyl)-4-methoxyphenylsulfonamido)-3-methylbutanoate 
• 1378928-85-8 4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)benzyl 2,2,2-trifluoroacetate 

Relevant articles and documents

A new class of highly potent matrix metalloproteinase inhibitors based on triazole-Substituted hydroxamates: (Radio)synthesis and in vitro and first in vivo evaluation

In vivo imaging of MMPs is of great (pre)clinical interest and can potentially be realized with modern three-dimensional and noninvasive in vivo molecular imaging techniques such as positron emission tomography (PET). Consequently, MMP inhibitors (MMPIs) radiolabeled with positron emitting nuclides (e.g., 18F) represent a suitable tool for the visualization of activated MMPs with PET. On the basis of our previous work and results regarding radiolabeled and unlabeled derivatives of the nonselective MMPIs, we discovered a new class of fluorinated MMPIs with a triazole-substituted hydroxamate substructure. These novel MMPIs are characterized by an increased hydrophilicity compared with the lead structures and excellent MMP inhibition potencies for MMP-2, MMP-8, MMP-9, and MMP-13 (IC50 = 0.006-107 nM). Therefore, one promising fluorinated triazole-substituted hydroxamate (30b) was selected and resynthesised as its 18F-labeled version to yield the potential PET radioligand [18F]30b. The biodistribution behavior of this novel compound was investigated with small animal PET.